StemRIM (TYO: 4599)

Japan flag Japan · Delayed Price · Currency is JPY
360.00
-6.00 (-1.64%)
Nov 1, 2024, 3:15 PM JST
-44.53%
Market Cap 22.15B
Revenue (ttm) n/a
Net Income (ttm) -2.02B
Shares Out 61.52M
EPS (ttm) -32.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 99,700
Open 363.00
Previous Close 366.00
Day's Range 355.00 - 363.00
52-Week Range 321.00 - 735.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Dec 11, 2024

About StemRIM

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. St... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 45
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4599
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.